TMCnet News

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
[August 10, 2018]

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm


The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or "the Company") (NASDAQ: TTPH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares pursuant and/or traceable to the July 2017 Secondary Offering, or between March 8, 2017, and February 13, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before September 25, 2018.

If you are a shareholder who suffered a loss, click here to participate.



We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA (News - Alert) 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.


According to the Complaint, the Company made false and misleading statements to the market. Tetraphase increased the number of patients enrolled in the IGNITE3 trial to 1,200 from its original 1,000 in an attempt to meet the trial's primary endpoints. The increase in enrolled patients indicates that the existing enrolled population was not adequate to meet these endpoints. Based on these facts, the Company's public statements about business operations and the IGNITE3 trial were false and materially misleading throughout the class period. When the market learned the truth about Tetraphase, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.


[ Back To TMCnet.com's Homepage ]